Thelansis

Charcot-Marie-Tooth Disease Type 2S (CMT2S) Market Outlook Thelansis’s “Charcot-Marie-Tooth Disease Type 2S (CMT2S) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Charcot-Marie-Tooth Disease Type 2S (CMT2S) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Key business questions answered: How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and patient share? Which even...

Charcot-Marie-Tooth Disease Type 2S (CMT2S) Market Outlook Thelansis’s “Charcot-Marie-Tooth Disease Type 2S (CMT2S) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Charcot-Marie-Tooth Disease Type 2S (CMT2S) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Charcot-Marie-Tooth Disease Type 2S (CMT2S) Overview Charcot-Marie-Tooth disease type 2S (CMT2S) is an autosomal recessive axonal neuropathy characterized by the progressive weakening and wasting of distal muscles in the lower and upper limbs, typically manifesting in the first decade of life. Patients with CMT2S exhibit reduced reflexes and varying degrees of sensory impairme...

Charcot-Marie-Tooth disease type 2S (CMT2S) is an autosomal recessive axonal neuropathy characterized by the progressive weakening and wasting of distal muscles in the lower and upper limbs, typically manifesting in the first decade of life. Patients with CMT2S exhibit reduced reflexes and varying degrees of sensory impairment, primarily affecting the distal regions. The underlying cause of CMT2S is a mutation in the IGHMBP2 gene. Mutations in the IGHMBP2 gene can result in two distinct phenotypes: 1) severe SMARD1 (Spinal Muscular Atrophy associated with Respiratory Distress) or 2) milder CMT2S. Both conditions are rare and exhibit recessive inheritance patterns. The specific mutations within the IGHMBP2 gene determine whether patients develop SMARD1, characterized by autosomal recessive mutations in IGHMBP2 that are unrelated to the myelin protein MBP, or CMT2S, which leads to a gradual progression of weakness, muscle wasting, and sensory loss associated with an axonal neuropathy typ...